Immunotherapy at UCL/UCLH Karl Peggs Professor of Transplant Science and Cancer Immunotherapy Scientific Director NIHR BTRU for Stem Cell Transplantation and Immunotherapy
An introduction to the immune system The opposite isn’t so great either This is your immune system. If the immune system is too weak, your body becomes It is vigilant on one end of a susceptible to infection. very complex balance. On the other end is your body, suspended over a sea of bacteria and viruses. The same is true of cancer, which suppresses immunity via a number of mechanisms. Immunotherapy aims to strengthen the ability of the immune system to fight cancer.
Mast cell B cell Macrophage Antibodies γδ T cell Basophil NK cell DCs T cell Eosinophil Complement protein NKT cell Neutrophil Granulocytes CD4 + cell CD8 + cell Innate Immunity Adaptive Immunity (rapid response) (slow response, memory) Innate immune system: involves proteins (chemokines and cytokines) and cells, is considered to be the first line of immune defense Adaptive immune system: mediated by B and T cells, is highly specific and capable of generating an antigen-specific response – Induction requires presentation of antigens by cells of the innate immune system
Antibodies as immunotherapies – original thinking
Antibodies – payload delivery 1 1 5 5 2 4 2 4 3 3 1 Antibody targets cell surface protein 2 Binding and internalization MMAE release: after internalization MMAE is released into the target cells 3 Microtubule disruption: binding of MMAE disrupts the microtubule network 4 Cell death: if microtubule disruption occurs, apoptotic cell death results 5
Antibodies - Immune Checkpoints APC/ T cell Tumour B7-2 (CD86) CD28 Activation B7-1 (CD80) CTLA-4 Inhibition PD-L1 PD-1 Inhibition Blocking antibodies targeting co-inhibitory receptors PD-L2 B7-1 (CD80) Inhibition LAG-3 Inhibition MHC TCR CD40 CD40L Activation Agonistic antibodies targeting co- CD137L CD137 Activation stimulatory receptors OX40L OX40 Activation
T cells and Tumour Control
T cells for relapsed disease after BMT Jan 03 - Aug 04 Nov 06 - Feb 08
Chimeric antigen receptors (CARs) CD19 CAR T cell trials: • COBALT: 2 nd generation CAR, bridge to allograft in DLBCL • D-CAR19: 2 nd generation CAR, for cancers relapsing post allograft • UniCAR19: 2 nd generation CAR, off the shelf third party treatment … paediatric ALL (CARPALL), adult ALL (i4i)
Delivery – a meeting of the minds U C L C A N C E R I N S T I T U T E
UCLH – state of the art immunotherapy service
UCL/UCLH – delivering the spectrum of cancer immunotherapy
Immunotherapy A new frontier Candace S. Johnson, PhD Immunotherapy is the
UCLH CANCER STRATEGY July 2015 Geoff Bellingan Medical Director, Surgery
UCLH Members Meet Pituitary disorders UCLH Department of Diabetes &
This is UCLH Introduction for prospective governors Liz Rose, Membership
Catering Dietitian at UCLH Catering Dietitian at UCLH Hasina Aktar Hasina
UCLH Members Meet: Arthritis Dr Jessica Manson June 2016 Structure of talk
Resuscitation Council Guidelines 2005 A Summary Resuscitation Service UCLH
Progress of cancer immunotherapy and its future perspectives Yutaka Kawakami
The immunotherapy of cancer: past, present & the next frontier Ira
GRAFT ENGINEERING AND CELLULAR IMMUNOTHERAPY What the present and future
Corporate Presentation June 2019 NASDAQ/TSX: TRIL This presentation may
NWCSAF Convection products: v2018 improvements, validation and adaptability
Mercer Island School District Long-Range Facility Plan 30 March 2020
CP Seminar 1 Housekeeping Items The City of Vancouver acknowledges that it
HNSON C UNTY C MMUNITY C LLEGE FACILITIES MASTER PLAN BOARD MEETING
National FFA Organization DELIVERY OF THE FFA MISSION College/career-
Reactivating the anti-tumor immune response by targeting innate and adaptive
Homeostatic Disruptions and the Immune System Disruptions to Dynamic
Immunobricks bricks Immuno Immunobricks Immunobricks toprepare ahi-tech
Te Tekna na CEPIs mission and activit vities ies rega garding ding COVI
ACTIVATING THE PATIENTS IMMUNE SYSTEM TO FIGHT CANCER Company presentation
KIADIS PHARMA | COMPANY PRESENTATION | NOVEMBER 2019 EURONEXT: KDS